# Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

> **NCT05354141** · PHASE3 · RECRUITING · sponsor: **Direct Biologics, LLC** · enrollment: 970 (estimated)

## Conditions studied

- Acute Respiratory Distress Syndrome
- ARDS

## Interventions

- **BIOLOGICAL:** ExoFlo
- **OTHER:** Intravenous normal saline

## Key facts

- **NCT ID:** NCT05354141
- **Lead sponsor:** Direct Biologics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-01
- **Primary completion:** 2027-11-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 970 (ESTIMATED)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05354141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05354141, "Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05354141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*